Literature DB >> 29134565

Prognostic value of FDG-PET and DWI in breast cancer.

Kazuhiro Kitajima1, Yasuo Miyoshi2, Toshiko Yamano3, Soichi Odawara3, Tomoko Higuchi2, Koichiro Yamakado3.   

Abstract

OBJECTIVE: To investigate the prognostic value of preoperative FDG-PET/CT and diffusion weighted imaging (DWI) in patients with breast cancer.
METHODS: A total of 73 patients with newly diagnosed invasive breast cancer who had undergone preoperative whole-body FDG-PET/CT and 3-Tesla breast MRI including DWI followed by surgery were identified. Effects of primary tumor PET parameters [maximum standardized uptake value (SUVmax), mean SUV (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)] and DWI parameters [mean apparent diffusion coefficient (ADCmean) and minimum ADC (ADCmin)] including clinicopathologic factors on disease-free survival (DFS) were retrospectively evaluated using the log-rank and Cox methods.
RESULTS: After a median overall follow-up of 32.3 months in all patients, 6 (8.2%) of the 73 patients had recurrence. Receiver operating characteristic curve analysis and log-rank tests showed that patients with a high primary tumor SUVmax (≥ 3.60), MTV (≥ 3.15), and TLG (≥ 16.0) had a significantly lower DFS rate than those with a low SUVmax (< 3.60), MTV (< 3.15), and TLG (< 16.0), respectively (p = 0.0054, p = 0.0054, and p < 0.0001, respectively). SUVmean, ADCmean, and ADCmin were not significantly associated with recurrence. Univariate analysis showed that SUVmax (p = 0.0054), MTV (p = 0.0054), TLG (p < 0.0001), tumor size (p = 0.0083), estrogen receptor negativity (p = 0.046), progesterone receptor negativity (p = 0.0023), human epidermal growth factor receptor 2 positivity (p = 0.043), and the presence of axillary lymph node metastasis (p = 0.0037) were also significantly associated with recurrence. However, in multivariate analysis, none of them were an independent factor.
CONCLUSIONS: The preoperative SUVmax, MTV, and TLG of primary breast cancer are prognostic factors for recurrence, whereas ADC values are not.

Entities:  

Keywords:  Breast cancer; DWI (diffusion weighted imaging); PET (positron emission tomography); Prognosis; TLG (total lesion glycolysis)

Mesh:

Substances:

Year:  2017        PMID: 29134565     DOI: 10.1007/s12149-017-1217-9

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  13 in total

1.  Prognostic value of SUVmax in breast cancer and comparative analyses of molecular subtypes: A systematic review and meta-analysis.

Authors:  Moon Il Lee; Youn Joo Jung; Dong Il Kim; Seungju Lee; Chang Shin Jung; Seok Kyung Kang; Kyoungjune Pak; Seong Jang Kim; Hyun Yul Kim
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

2.  Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.

Authors:  Hung-Pin Chan; Wen-Shan Liu; Wen-Shiung Liou; Chin Hu; Yu-Li Chiu; Nan-Jing Peng
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  Usefulness of Preoperative 18F-FDG PET/CT for Patients with Thymic Epithelial Tumors.

Authors:  Mana Ishibashi; Yoshio Tanabe; Hiroto Yunaga; Hidenao Miyoshi; Ken Miwa; Hiroshige Nakamura; Shinya Fujii; Toshihide Ogawa
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

4.  Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

5.  Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-A systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  PLoS One       Date:  2019-06-17       Impact factor: 3.240

6.  Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

7.  FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond.

Authors:  Malene Grubbe Hildebrandt; Jeppe Faurholdt Lauridsen; Marianne Vogsen; Jorun Holm; Mie Holm Vilstrup; Poul-Erik Braad; Oke Gerke; Mads Thomassen; Marianne Ewertz; Poul Flemming Høilund-Carlsen
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

8.  Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F-FDG PET/CT for Patients with Colorectal Cancer.

Authors:  Xin Liu; Kun Xiang; Guang-Yong Geng; Shi-Cun Wang; Ming Ni; Yi-Fan Zhang; Hai-Feng Pan; Wei-Fu Lv
Journal:  Contrast Media Mol Imaging       Date:  2022-01-30       Impact factor: 3.161

9.  Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: A systematic review and meta-analysis.

Authors:  Weibo Wen; Dongchun Xuan; Yulai Hu; Xiangdan Li; Lan Liu; Dongyuan Xu
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

10.  Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients.

Authors:  Cornelis Maarten de Mooij; Inés Sunen; Cristina Mitea; Ulrich C Lalji; Sigrid Vanwetswinkel; Marjolein L Smidt; Thiemo J A van Nijnatten
Journal:  Nucl Med Commun       Date:  2020-10       Impact factor: 1.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.